Summary
In pretreated breast cancer, encouraging therapy responses are regularly achieved by applying innovative therapies. We present here a case report of a woman with a 10-year history of breast cancer with continuous progression despite multiple therapies. Ultimately, ascitic effusion developed, massively disturbing her quality of life. A combination of bevacizumab and mitoxantrone/methotrexate chemotherapy led to a striking, response on liver metastasis and effusion generation, with great clinical benefit. Our case highlights previous observations that bevacizumab is beneficial in inhibiting the production of malignant effusion.
This is a preview of subscription content, log in via an institution to check access.
References
Tokunaga E, Oki E, Nishida K, Koga T, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol, 11: 199–208, 2006
Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3: 24–40, 2006
Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med, 353: 740–741, 2005
Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol, 102: 425–428, 2006
Harper-Wynne C, English J, Meyer L, Bower M, et al. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer, 81: 316–322, 1999
Miller K, Wang M, Gralow J, Dickler M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357: 2666–2676, 2007
Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol, 23: 792–799, 2005
Verheul HM, Hoekman K, Jorna AS, Smitt EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist, 5(Suppl 1): 45–50, 2000
Nagy JA, Masse EM, Herzberg KT, Meyers MS, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res, 55: 360–368, 1995
Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol, 153: 1249–1256, 1998
Hu L, Hofmann J, Zaloudek C, Ferrara N, et al. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol, 161: 1917–1924, 2002
Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol, 17: 1853, 2006
Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res, 65: 671–680, 2005
Ramaswamy B, Elias AD, Kelbick NT, Dodley A, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res, 12: 3124–3129, 2006
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prassl, K., Sahanic, A., Reicher, B. et al. Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation. memo 1, 149–151 (2008). https://doi.org/10.1007/s12254-008-0051-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0051-0